68 related articles for article (PubMed ID: 26943913)
1. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
Takagi M; Miki Y; Miyashita M; Hata S; Yoda T; Hirakawa H; Sagara Y; Rai Y; Ohi Y; Tamaki K; Ishida T; Suzuki T; Ouchi N; Sasano H
Breast Cancer Res Treat; 2016 Feb; 156(1):45-55. PubMed ID: 26943913
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
Yoda T; McNamara KM; Miki Y; Takagi M; Rai Y; Ohi Y; Sagara Y; Tamaki K; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
Cancer Sci; 2014 Nov; 105(11):1503-9. PubMed ID: 25230018
[TBL] [Abstract][Full Text] [Related]
3. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
[TBL] [Abstract][Full Text] [Related]
4. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism.
Du T; Zhu L; Levine KM; Tasdemir N; Lee AV; Vignali DAA; Houten BV; Tseng GC; Oesterreich S
Sci Rep; 2018 May; 8(1):7205. PubMed ID: 29739984
[TBL] [Abstract][Full Text] [Related]
5. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
[TBL] [Abstract][Full Text] [Related]
6. The myoepithelial cell layer may serve as a potential trigger factor for different outcomes of stage-matched invasive lobular and ductal breast cancers.
Hsiao YH; Tsai HD; Chou MC; Man YG
Int J Biol Sci; 2011 Feb; 7(2):147-53. PubMed ID: 21326853
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
Djerroudi L; El Sabeh-Ayoun A; Benoist C; Pierron G; Masliah-Planchon J; Fuhrmann L; Kieffer Y; Carton M; Ramtohul T; Callens C; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
Mod Pathol; 2024 May; 37(5):100463. PubMed ID: 38428737
[TBL] [Abstract][Full Text] [Related]
8. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer.
Purohit A; Newman SP; Reed MJ
Breast Cancer Res; 2002; 4(2):65-9. PubMed ID: 11879566
[TBL] [Abstract][Full Text] [Related]
9. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
10. Relevance of systems biological approach in the differential diagnosis of invasive lobular carcinoma & invasive ductal carcinoma.
Ragunath PK; Reddy BV; Abhinand PA; Ahmed SS
Bioinformation; 2012; 8(8):359-64. PubMed ID: 22570516
[TBL] [Abstract][Full Text] [Related]
11. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights.
Batra H; Mouabbi JA; Ding Q; Sahin AA; Raso MG
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001750
[TBL] [Abstract][Full Text] [Related]
12. A Path to Precision Metabolic Treatment in Breast Cancer: Riluzole, Glutamate Signaling, and Invasive Lobular Carcinoma.
Sikora MJ; Ostrander JH
J Endocr Soc; 2024 Jan; 8(2):bvad171. PubMed ID: 38193025
[No Abstract] [Full Text] [Related]
13. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
[TBL] [Abstract][Full Text] [Related]
14. Bivalent Approach for Homodimeric Estradiol Based Ligand: Synthesis and Evaluation for Targeted Theranosis of ER(+) Breast Carcinomas.
Chauhan K; Arun A; Singh S; Manohar M; Chuttani K; Konwar R; Dwivedi A; Soni R; Singh AK; Mishra AK; Datta A
Bioconjug Chem; 2016 Apr; 27(4):961-72. PubMed ID: 26999669
[TBL] [Abstract][Full Text] [Related]
15. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
16. Proceedings of the 5th Kuwait International Pharmacy Conference, February 1-3, 2015.
Phillips OA; Al-Soraj M
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):1-2. PubMed ID: 26986015
[No Abstract] [Full Text] [Related]
17. Androgen and breast cancer: an update.
McNamara KM; Sasano H
Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):249-56. PubMed ID: 26945136
[TBL] [Abstract][Full Text] [Related]
18. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.
Stecklein SR; Shen X; Mitchell MP
Clin Breast Cancer; 2016 Aug; 16(4):319-26. PubMed ID: 26943990
[TBL] [Abstract][Full Text] [Related]
19. Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S; Miyashita M; Maeda I; Goda A; Tada H; Amari M; Kojima Y; Tsugawa K; Ohi Y; Sagara Y; Sato M; Ebata A; Harada-Shoji N; Suzuki T; Nakanishi M; Ohta T; Ishida T
Breast Cancer Res Treat; 2024 Apr; 204(3):453-463. PubMed ID: 38180699
[TBL] [Abstract][Full Text] [Related]
20. Targeting sex steroid biosynthesis for breast and prostate cancer therapy.
Poutanen M; Hagberg Thulin M; Härkönen P
Nat Rev Cancer; 2023 Sep; ():. PubMed ID: 37684402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
